SEC Form 6-K filed by Ascentage Pharma Group International
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2025
Commission File Number: 001-42484
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
On April 28, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax.” A copy of the announcement is furnished as Exhibit 99.1 to this Report.
In addition, on April 28, 2025, the Company issued a Hong Kong Stock Exchange voluntary announcement entitled, “Ascentage Pharma Presents Results From Five Preclinical Studies At 2025 American Association Of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects Of Olverembatinib Combined With Lisaftoclax”. A copy of the announcement is furnished as Exhibit 99.2 to this Report.
1
INDEX TO EXHIBITS
Exhibit Number | Exhibit Title | |
99.1 | Press Release dated April 28, 2025 | |
99.2 | Hong Kong Stock Exchange Voluntary Announcement dated April 28, 2025 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ASCENTAGE PHARMA GROUP INTERNATIONAL | |
Date: April 28, 2025 | /s/ Dajun Yang |
Name: Dajun Yang | |
Title: Chief Executive Officer |
3